Cargando…
Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company
OBJECTIVES: Evidence requirements and assessment methods access differ between health technology assessment (HTA) agencies. The HTA Core Model(®) provides a standardized approach to HTA, targeting evidence sharing and collaboration between participating HTA bodies. It is fit for purpose from an indu...
Autores principales: | Ducournau, Pierre, Irl, Cornelia, Tatt, Iain, McCarvil, Mary, Gyldmark, Marlene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521787/ https://www.ncbi.nlm.nih.gov/pubmed/30789111 http://dx.doi.org/10.1017/S0266462318003653 |
Ejemplares similares
-
Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018) -
PNS173 Impact of COVID-19 on HTA Bodies and Pharmaceutical Company Pricing and Market Access Activities
por: Thomas, M., et al.
Publicado: (2020) -
Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia
por: Al-Omar, Hussain Abdulrahman, et al.
Publicado: (2020) -
The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018) -
Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)